Company news: Elsevier, Abbott

Share this article:

Elsevier printed the inaugural issue of its Operations Research for Health Care journal in March. The company says the quarterly publication will help researchers, teachers and practitioners interested in research techniques for optimal healthcare delivery. The journal will include series of communications for clinicians, managers and decision makers.

Abbott Labs is one step closer to splitting into two. The company announced Wednesday that its research-based company will be named AbbVie when the pharma co divides into a medical products company named Abbott, and a research company at the end of this year. The Abb-plus name “connects the new company to Abbott and its heritage of pioneering science,” Richard Gonzalez, global pharmaceuticals EVP said in a statement. As AbbVie's chair and CEO, Gonzalez will oversee a portfolio that includes Humira, Lupron and Kaletra.

Amgen's new CEO Robert Bradway will get a $1.4 million raise when he takes his new job May 23. The bump amounts to a 36% increase over his current salary, and was announced along with an increase in target cash incentives for the company's executive vice presidents. Current CEO Kevin Sharer will stay on as Chairman of the Board through 2012 and will continue to be paid at his current salary.
Share this article:

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.